TY - JOUR
T1 - Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors
T2 - A comparative study
AU - Saludas, Laura
AU - Garbayo, Elisa
AU - Ruiz-Villalba, Adrián
AU - Hernández, Silvia
AU - Vader, Pieter
AU - Prósper, Felipe
AU - Blanco-Prieto, María J.
N1 - Funding Information:
This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2017-83734-R). L. Saludas thanks the “Asociación de Amigos de la Universidad de Navarra” and “La Caixa” banking foundation. Elisa Garbayo is supported by an FSE/Ministry of Science and innovation-State Research Agency/ RYC2018-025897-I. Adrian Ruiz-Villalba was supported by the Spanish Ministry of Sciences and Innovations FSE/MINECO-AEI(IJCI-2016-30254) and the University of Málaga . This work was supported by the ISCIII and co-financed by FEDER Red TERCEL RETIC RD16/0011/0005 and MINECO (Program RETOS Cardiomesh RTC-2016-4911-1 ), ERANET II (Nanoreheart AC15/00050 ), CIBERONC CB16/12/00489 and EU’s H2020 Programme for research, technological development and demonstration under grant agreement BRAV ∃-874827 .
Funding Information:
This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2017-83734-R). L. Saludas thanks the ?Asociaci?n de Amigos de la Universidad de Navarra? and ?La Caixa? banking foundation. Elisa Garbayo is supported by an FSE/Ministry of Science and innovation-State Research Agency/ RYC2018-025897-I. Adrian Ruiz-Villalba was supported by the Spanish Ministry of Sciences and Innovations FSE/MINECO-AEI(IJCI-2016-30254) and the University of M?laga. This work was supported by the ISCIII and co-financed by FEDER Red TERCEL RETIC RD16/0011/0005 and MINECO (Program RETOS Cardiomesh RTC-2016-4911-1), ERANET II (Nanoreheart AC15/00050), CIBERONC CB16/12/00489 and EU's H2020 Programme for research, technological development and demonstration under grant agreement BRAV?-874827.
Publisher Copyright:
© 2021 The Authors
PY - 2022/1
Y1 - 2022/1
N2 - Since the discovery of the beneficial therapeutical effects of extracellular vesicles (EVs), these agents have been attracting great interest as next-generation therapies. EVs are nanosized membrane bodies secreted by all types of cells that mediate cell–cell communication. Although the classification of different subpopulations of EVs can be complex, they are broadly divided into microvesicles and exosomes based on their biogenesis and in large and small EVs based on their size. As this is an emerging field, current investigations are focused on basic aspects such as the more convenient method for EV isolation. In the present paper, we used cardiac progenitor cells (CPCs) to study and compare different cell culture conditions for EV isolation as well as two of the most commonly employed purification methods: ultracentrifugation (UC) and size-exclusion chromatography (SEC). Large and small EVs were separately analysed. We found that serum starvation of cells during the EV collecting period led to a dramatic decrease in EV secretion and major cell death. Regarding the isolation method, our findings suggest that UC and SEC gave similar EV recovery rates. Separation of large and small EV-enriched subpopulations was efficiently achieved with both purification protocols although certain difference in sample heterogeneity was observed. Noteworthy, while calnexin was abundant in large EVs, ALIX and CD63 were mainly found in small EVs. Finally, when the functionality of EVs was assessed on primary culture of adult murine cardiac fibroblasts, we found that EVs were taken up by these cells, which resulted in a pronounced reduction in the proliferative and migratory capacity of the cells. Specifically, a tendency towards a larger effect of SEC-related EVs was observed. No differences could be found between large and small EVs. Altogether, these results contribute to establish the basis for the use of EVs as therapeutic platforms, in particular in regenerative fields.
AB - Since the discovery of the beneficial therapeutical effects of extracellular vesicles (EVs), these agents have been attracting great interest as next-generation therapies. EVs are nanosized membrane bodies secreted by all types of cells that mediate cell–cell communication. Although the classification of different subpopulations of EVs can be complex, they are broadly divided into microvesicles and exosomes based on their biogenesis and in large and small EVs based on their size. As this is an emerging field, current investigations are focused on basic aspects such as the more convenient method for EV isolation. In the present paper, we used cardiac progenitor cells (CPCs) to study and compare different cell culture conditions for EV isolation as well as two of the most commonly employed purification methods: ultracentrifugation (UC) and size-exclusion chromatography (SEC). Large and small EVs were separately analysed. We found that serum starvation of cells during the EV collecting period led to a dramatic decrease in EV secretion and major cell death. Regarding the isolation method, our findings suggest that UC and SEC gave similar EV recovery rates. Separation of large and small EV-enriched subpopulations was efficiently achieved with both purification protocols although certain difference in sample heterogeneity was observed. Noteworthy, while calnexin was abundant in large EVs, ALIX and CD63 were mainly found in small EVs. Finally, when the functionality of EVs was assessed on primary culture of adult murine cardiac fibroblasts, we found that EVs were taken up by these cells, which resulted in a pronounced reduction in the proliferative and migratory capacity of the cells. Specifically, a tendency towards a larger effect of SEC-related EVs was observed. No differences could be found between large and small EVs. Altogether, these results contribute to establish the basis for the use of EVs as therapeutic platforms, in particular in regenerative fields.
KW - Cardiovascular progenitors
KW - Large and small extracellular vesicles
KW - Size-exclusion chromatography
KW - Ultracentrifugation
UR - https://www.scopus.com/pages/publications/85122139548
U2 - 10.1016/j.ejpb.2021.12.012
DO - 10.1016/j.ejpb.2021.12.012
M3 - Article
C2 - 34968647
AN - SCOPUS:85122139548
SN - 0939-6411
VL - 170
SP - 187
EP - 196
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
ER -